Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Less chemotherapy better for older patients with advanced stomach and oesophageal cancers

Lower doses of chemotherapy were as effective at controlling disease for elderly or frail patients with advanced cancer of the stomach or oesophagus and spared them less diarrhoea and lethargy side effects.

Lower doses of chemotherapy were as effective at controlling disease for elderly or frail patients with advanced cancer of the stomach or oesophagus and spared them less diarrhoea and lethargy side effects. These are the results of the GO2 trial, a Cancer Research UK funded study, that could change the standard of care for patients who can’t have full dose chemotherapy due to their age, frailty or medical fitness. The study, which ran at hospitals all over the UK, coordinated from the University of Leeds, involved 514 people with stomach or oesophageal cancer. Their average age was 76 and the oldest was 96 years old. All

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy